Having trouble accessing articles? Reset your cache.

Bayer reports rivaroxaban data

Bayer AG (Xetra:BAY) said oral rivaroxaban was non-inferior to current standard therapy on the primary endpoint

Read the full 162 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE